dc.contributor.author |
Jarrin, Inma |
dc.contributor.author |
Pantazis, Nikos |
dc.contributor.author |
Dalmau, Judith |
dc.contributor.author |
Phillips, Andrew N. |
dc.contributor.author |
Olson, Ashley |
dc.contributor.author |
Mussini, Cristina |
dc.contributor.author |
Boufassa, Faroudy |
dc.contributor.author |
Costagliola, Dominique |
dc.contributor.author |
Porter, Kholoud |
dc.contributor.author |
Blanco, Julià |
dc.contributor.author |
Del Amo, Julia |
dc.contributor.author |
Martínez Picado, Francisco Javier |
dc.date |
2015 |
dc.identifier |
https://ddd.uab.cat/record/185466 |
dc.identifier |
urn:10.1097/QAD.0000000000000805 |
dc.identifier |
urn:oai:ddd.uab.cat:185466 |
dc.identifier |
urn:pmid:26544704 |
dc.identifier |
urn:pmcid:PMC5629982 |
dc.identifier |
urn:pmc-uid:5629982 |
dc.identifier |
urn:articleid:14735571v29p2323 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/c6fea53a-9db4-44c8-a7d4-90ddd4460a90 |
dc.identifier |
urn:scopus_id:84957636324 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5629982 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
European Commission 260694 |
dc.relation |
AIDS (London, England) ; Vol. 29 (october 2015), p. 2323-2333 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
dc.rights |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.subject |
CD4 responses |
dc.subject |
HIV-viral suppression |
dc.subject |
Rapid progression |
dc.title |
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved? |
dc.type |
Article |
dc.description.abstract |
This article compares trends in CD4 + T-cell recovery and proportions achieving optimal restoration (≥500 cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4 + less than 200 cells/μl within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4 + T-cell count at cART start (baseline), rapid progressors experienced faster CD4 + T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1-18 [−0.05 (−0.06; −0.03)] and no significant differences in 18-60 months [−0.003 (−0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4 + T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4 + T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4 + T-cell counts at cART initiation. |